Grafa News and Videos — Page 74

Cemex (NYSE:CX) reported third-quarter 2026 revenue of $4.59 billion, an increase of 8% from $4.25 billion a year earlier, surpassing Wall Street's consensus estimate of $4.45 billion.

MakeMyTrip Limited (NASDAQ:MMYT) reported fiscal second-quarter 2027 revenue of $235.2 million, an increase of 2.5% year over year, although the figure fell short of analysts' expectations of approximately $267.4 million to $269.1 million.

Citizens Community Bancorp (NASDAQ:CZWI) reported third-quarter 2026 net income of $5.4 million, compared with $1.1 million in the preceding quarter and $3.7 million a year earlier, while diluted earnings reached $0.56 per share.

XTEND AI Robotics (NYSE:XTND) announced preliminary, unaudited financial results projecting total revenue of $24.5 million to $26.5 million for the nine months ended September 30, 2026, exceeding its full-year 2025 revenue.

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, a 19.4% decline from $89.4 million a year earlier, while its net loss widened to $17.5 million, or $1.57 per share, from $2.3 million, or $0.21 per share.

Lakeland Financial Corporation (NASDAQ:LKFN) reported record third-quarter 2026 net income of $28.9 million, an increase of 9% from $26.4 million a year earlier, while diluted earnings per share rose 11% to $1.14.

Sierra Bancorp (NASDAQ:BSRR) reported record third-quarter 2026 net income of $15.3 million, a 58% increase from $9.7 million a year earlier, while diluted earnings per share climbed 64% to $1.18 from $0.72.

S&P Global (NYSE:SPGI) has completed its acquisition of blockchain security company OpenZeppelin, expanding its digital asset risk assessment capabilities to cover the technology underlying tokenized financial products and decentralized finance.

Regeneron Pharmaceuticals (NASDAQ:REGN) announced a $270 million extension of its agreement with the Biomedical Advanced Research and Development Authority to supply additional doses of Inmazeb for U.S. preparedness against Ebola outbreaks.

Fate Therapeutics (NASDAQ:FATE) presented preliminary Phase 1 clinical results for FT819 showing renal responses in two evaluable patients with lupus nephritis, a serious kidney complication of systemic lupus erythematosus.